Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis

被引：1

作者：

James R. Spalding

Joel Hay

机构：

[1] Astellas Pharma US,Department of Pharmaceutical Economics and Policy

[2] School of Pharmacy,undefined

[3] University of Southern California,undefined

来源：

PharmacoEconomics | 2006年 / 24卷

关键词：

Rheumatoid Arthritis; Methotrexate; Infliximab; Etanercept; Adalimumab;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1221 / 1232

页数：11

共 50 条

[1] Cost effectiveness of tumour necrosis factor-α inhibitors as first-line agents in rheumatoid arthritis
Spalding, James R.
Hay, Joel
[J]. PHARMACOECONOMICS, 2006, 24 (12) : 1221 - 1232
[2] Cost-effectiveness of tumor necrosis factor alpha (TNF-alpha) inhibitors as first-line agents in rheumatoid arthritis
Spalding, JR
Hay, JW
[J]. VALUE IN HEALTH, 2004, 7 (03) : 241 - 241
[3] Tumour necrosis factor-α inhibitors are glucocorticoid-sparing in rheumatoid arthritis
Nilsson, Anna Christine
Christensen, Anne Friesgaard
Junker, Peter
Lindegaard, Hanne Merete
[J]. DANISH MEDICAL BULLETIN, 2011, 58 (04)
[4] Perforating folliculitis associated with tumour necrosis factor-α inhibitors administered for rheumatoid arthritis
Gilaberte, Y.
Coscojuela, C.
Vazquez, C.
Rosello, R.
Vera, J.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (02) : 368 - 371
[5] Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors
Mewar, Devesh
Wilson, Anthony G.
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2011, 162 (04) : 785 - 791
[6] Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-α antagonists
Isaacs, John D.
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (12) : 1463 - 1475
[7] The case of tumour necrosis factor-α inhibitors in the treatment of rheumatoid arthritis -: A budget impact analysis
Sorensen, J
Andersen, LS
[J]. PHARMACOECONOMICS, 2005, 23 (03) : 289 - 298
[8] Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study
Pappas, Dimitrios A.
St John, Gregory
Etzel, Carol J.
Fiore, Stefano
Blachley, Taylor
Kimura, Toshio
Punekar, Rajeshwari
Emeanuru, Kelechi
Choi, Jeannie
Boklage, Susan
Kremer, Joel M.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (01) : 96 - 102
[9] Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis An Application of Bayesian Methods for Evidence Synthesis in a Markov Model
Nguyen, Christine M.
Bounthavong, Mark
Mendes, Margaret A. S.
Christopher, Melissa L. D.
Tran, Josephine N.
Kazerooni, Rashid
Morreale, Anthony P.
[J]. PHARMACOECONOMICS, 2012, 30 (07) : 575 - 593
[10] Correspondence to 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study'
Zheng, Wenjie
Leong, Pui-Ying
Wei, James Cheng-Chung
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (11)

← 1 2 3 4 5 →